MedX Health Corp. Announces Approval of Debt Settlement and AGM Results

MedX Health Corp. ("MedX" or the "Company") (TSX VENTURE:MDX) announces that at
its Annual and Special Meeting of Shareholders held on June 24, 2014, all
resolutions proposed to shareholders were duly passed, including the approval of
the issuance of 1,742,415 common shares relating to a settlement in November,
2013 of $435,603 of debt due to insiders of the Company. During the meeting,
Gary Van Nest, David Hennigar, Steven Guillen, Ken McKay and Robert von der
Porten were re-elected to the Board of Directors. 


Following the foregoing issuance of shares in settlement of debt, MedX will have
70,637,072 shares outstanding. 


About MedX 

MedX is headquartered in Mississauga, Ontario (Toronto), and is a global leader
in the design, manufacturing and distribution of quality low level laser and
light therapy technologies for use in numerous medical settings, including
rehab/chiropractic, dental, wound care, and veterinary medicine, providing
patients with drug free and non-invasive treatment of tissue damage and pain.
MedX laser and light products are FDA approved, Health Canada cleared, and CE
Mark approved for use in North America as well as the European Union. MedX's
products include SIMSYS(TM) and MoleMate(TM), which are approved by Health
Canada, and available to Canadian physicians and dermatologists, are FDA
approved for use in the USA, CE approved for use in Europe and the UK, and under
review in Australia, as an optical biopsy that uses patented technology
featuring a hand-held scanner device designed for clinical use that utilizes
light to view beneath suspicious moles or lesions in a pain free, non-invasive
manner, creating images in real-time for physicians and dermatologists to
evaluate all types of moles or lesions within seconds. For more information log
onto: www.simsys-molemate.com. For a complete profile of MedX and its products
visit www.medxhealth.com. 


This press release does not constitute an offer of any securities for sale. This
press release contains certain forward-looking statements within the meaning of
applicable Canadian securities legislation. These forward-looking statements
involve certain risks and uncertainties that could cause actual results to
differ, including, without limitation, the company's limited operating history
and history of losses, the inability to successfully obtain further funding, the
inability to raise capital on terms acceptable to the company, the inability to
compete effectively in the marketplace, the inability to complete the proposed
acquisition and such other risks that could cause the actual results to differ
materially from those contained in the company's projections or forward-looking
statements. All forward looking statements in this press release are based on
information available to the company as of the date hereof, and the company
undertakes no obligation to update forward-looking statements to reflect events
or circumstances occurring after the date of this press release. 


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this press release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
MedX Health Corp.
Robert von der Porten
President and CEO
905 670 4428
investor@medxhealth.com
www.medxhealth.com

Medx Health (TSXV:MDX)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024